Yale scientists publish largest genetic analysis of #neuroendocrine tumors of the cervix (NETc) showing tumors with a higher number of mutations are potentially more sensitive to #immunotherapy .
PNASNews Smilow Cancer Hospital Yale School of Medicine #gyncsm
yalecancercenter.org/news-article/g…

Learn what noninvasive treatment may help counteract “chemo brain,” which is characterized by memory loss and other cognitive effects caused by chemotherapy agents such as cisplatin, according to findings from Massachusetts Institute of Technology (MIT) researchers. #ChemoBrain #GynCSM news.mit.edu/2024/noninvasi…

Uterine cancer is on the rise. Check out our latest episode on uterine cancer before we drop our new episode on management of advanced and recurrent endometrial cancer tomorrow!

Podcast available here: podcasts.apple.com/us/podcast/rea…

#uterinecancer #endometrialcancer #gynonc #gyncsm

Cancer patients cannot afford to delay treatment due to #drugshortages . @senatormenendez, please work with your colleagues on both sides of the aisle to address these shortages. #ASCOAdvocacy #gyncsm

Approaches in the management of endometrial cancer are shifting towards precision medicine, with the goal of leveraging molecular subtypes to more accurately predict responses. Sylvester Comprehensive Cancer Center #gyncsm #oncology onclive.com/view/improved-…

I can't make it to DC for the ASCO Advocacy Day but I can send emails and let legislators know about #CancerResearch #drugshortages #telehealth issues important to the care cancer patients/ survivors asco.quorum.us/action_center/… #gyncsm

#WOCD2024 #WorldOvarianCancerDay is next month on May 8th. Everyone with ovarian cancer deserves the best possible care- no matter where they live! #gyncsm What can you do ? See World Ovarian Cancer Day & WOCCoalition worldovariancancercoalition.org/world-ovarian-… for more information.

Insanely proud of, and grateful for, you both!
#PatientAdvocacy #ResearchAdvocacy #PolicyAdvocacy
#bcsm #crcsm #gyncsm #lcsm #mmsm

#gyncsm are you an patient or research advocate? Check out AdvocateCollaborative (ACE) 's page and join us. Make connections and advance cancer advocacy across cancer types. advocatecollaborative.org

Now online in Journal of Clinical Oncology, the results of NRG Oncology The GOG Foundation Inc. #279: #Phase II Trial of #Cisplatin , #Gemcitabine , and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma

#IMRT #vulvarcancer #ClinicalTrials #gyncsm Vulvar Cancer Vulvar Cancer

‘Patient Is Otherwise Healthy’ | JCO Oncology Practice ascopubs.org/doi/full/10.12… #gyncsm Yes, we survive but the side effects of treatments - surgery to chemo to targeted therapies can cause issues with our health years later.

Abdominal pain is one of the top symptoms of #OvarianCancer .

So, what does it feel like?

Our Dr. Pamela Solima explains: brnw.ch/21wIRSj Pamela T. Soliman MD #GynCSM #EndCancer

I am grateful to AACR and AACRPres for recognizing true urgency of needs and shining a spotlight on #EndometrialCancer . As a patient, survivor, and #advocate , thank you for the power of your voice. Congratulations Emma Crosbie & #TeamWomb .
#AACR24 #GynCSM #OCRAhope #cancer

Pathbreaking Advances in Rare Ovarian Cancers by Dr. Rachel Grisham was a 💯 at ZEAL FOR TEAL! Now available On Demand on our YouTube.
Subscribe. Watch. Share! #ZealForTeal24 Team Ovary, Memorial Sloan Kettering Cancer Center GYN Cancer | #GYNCSM
WATCH full video: youtu.be/20_XhLVDECI?fe…

First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer Guy's and St Thomas' @gsttresearch @sgo_org #SGOMtg #gyncsm
onclive.com/view/first-lin…

#Drugshortages are impacting thousands of individuals w/ cancer, including individuals with cancer in our state @senbooker. Time is not on our side. Please work with your colleagues to mitigate these shortages. #ASCOAdvocacy #gyncsm

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer ascopost.com/news/april-202… #gyncsm #ovariancancer #SGO24 #SGO2024 SGO

Upifitamab rilsodotin failed to meet the primary end point of ORR in the phase 1/2 UPLIFT trial of NaPi2b-positive platinum-resistant high-grade serous ovarian cancer. @debbieric23 OU Health Stephenson Cancer Center @oucollegeofmed OU Health @sgo_org #SGOMtg #gyncsm onclive.com/view/journey-e…

In patients with platinum-sensitive disease who received rintatolimod plus pembrolizumab and cisplatin:
ORR: 45%
CBR: 55%
Median PFS: 7.8 months

#gyncsm

cancernetwork.com/view/rintatoli…